ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

 
Print Page
Email Article

Antibiotics Not Effective in Post-Lyme Syndrome (A Variant of Chronic Fatigue Syndrome?)

  [ 153 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 23, 2003


By Laurie Barclay, M.D.

Antibiotics do not improve cognitive symptoms of post-treatment chronic Lyme disease (PTCLD), according to the results of two randomized trials published in the June 24, 2003 issue of Neurology. The editorialist suggests that they should not be used in this condition, which may be a variant of chronic fatigue syndrome.

"Although encephalopathic symptoms have been attributed to PTCLD, objective evidence of cognitive dysfunction has been inconclusive and comes from a few relatively small studies," write Richard F. Kaplan, Ph.D., from the University of Connecticut School of Medicine in Farmington, and colleagues. "Moreover, there is little evidence that additional antibiotic therapy will improve cognitive functioning in this population."

Of 129 patients with Lyme disease diagnosed at three study sites in the northeast U.S., 78 were seropositive for IgG antibodies against Borrelia burgdorferi, and 51 were seronegative. In each group, patients were randomized to receive intravenous ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days, or matching intravenous and oral placebos.

At baseline, there were no significant differences between seropositive and seronegative groups. Both groups reported many symptoms on the cognitive functioning, pain, and role functioning scales of the Medical Outcomes Study (MOS), as well as depression and somatic complaints on the Beck Depression Inventory and Minnesota Multiphasic Personality Inventory. However, both groups had normal baseline neuropsychological test scores for memory, attention, and executive functioning.

Between baseline and 90 days, the combined groups showed significant decreases in MOS symptoms, higher objective test scores, and improved mood, but there were no significant differences between patients receiving antibiotics and those receiving placebo.

"Patients with post-treatment chronic Lyme disease who have symptoms but show no evidence of persisting Borrelia infection do not show objective evidence of cognitive impairment," the authors write. "Additional antibiotic therapy was not more beneficial than administering placebo.... We suspect that the improvement on tests involving sustained attention and speed of processing was a combination of practice effect, less pain, and improved mood."
The National Institutes of Health supported this study.

In a separate study, L. B. Krupp, M.D., and colleagues, from Stony Brook University Medical Center in New York, evaluated 55 patients with Lyme disease with severe fatigue persisting at least six months after antibiotic therapy. In this single-center, double-masked trial, patients were randomized to receive 28 days of intravenous ceftriaxone or placebo.

Compared with the placebo group, patients in the ceftriaxone group had improvement in disabling fatigue (rate ratio, 3.5; 95% confidence interval, 1.50 - 8.03; P = .001). However, antibiotic treatment was not associated with improvements in cognitive function, defined by a change of at least 25% on a test of reaction time, or in the laboratory measure (outer surface protein A) of persistent infection. Of four patients who had adverse treatment events requiring hospitalization, three were receiving placebo.

The authors note that masking may have been compromised, because more patients in the ceftriaxone group than in the placebo-treated group correctly guessed their treatment assignment.

"Because fatigue (a nonspecific symptom) was the only outcome that improved and because treatment was associated with adverse events, this study does not support the use of additional antibiotic therapy with parenteral ceftriaxone in post-treatment, persistently fatigued patients with [PTCLD]," the authors write. "Nonetheless, the improvement in fatigue could be considered an encouraging finding in that future studies exploring other less expensive and noninvasive methods for treating severe fatigue might be effective."

Roche Laboratories supplied the active medication and placebo.

In an accompanying editorial, Israel Steiner, from Hadassah University Hospital in Jerusalem, Israel, notes that patient groups studied were heterogeneous, which may have obscured positive therapeutic findings.

"What are the take-home messages?" he writes. "Although these studies do not provide credence to the possibility that [PTCLD] is due to an infective process, at present the interpretation of the data does not prove that the condition does not exist, that there is no ongoing infection, or that the treatment protocols are or are not the appropriate ones. Most importantly, without an objective surrogate (preferably biological) marker to enable recruitment of homogenous study groups, every attempt to address clinical questions in the realm of [PTCLD] is doomed, almost by definition, to leave these questions unsettled."

Study Reference: Neurology. 2003;60:1888-1889, 1916-1922, 1923-1930
Reviewed by Gary D. Vogin, M.D.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Bone Broth Benefits for Digestion, Arthritis and Cellulite Bone Broth Benefits for Digestion, Arthritis and Cellulite
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map